Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00795158
Other study ID # P02988
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 2002
Est. completion date January 2004

Study information

Verified date February 2022
Source Organon and Co
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to determine the effect of desloratadine treatment on quality of life, daytime functioning, quality of sleep, symptoms, and disease severity in patients who had hives for 6 weeks or longer. Patients took desloratadine for 1 month. Once a week, patients filled out a questionnaire to tell how their hives affected their lives. This questionnaire is called the Dermatology Life Quality Index or DLQI. They also filled out a diary every day to tell how much itching they had, how many hives they had, and how their hives had affected their sleep or daily activities. The patients and doctors rated the patients' overall condition and how much relief patients got from treatment.


Recruitment information / eligibility

Status Completed
Enrollment 282
Est. completion date January 2004
Est. primary completion date January 2004
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects must demonstrate their willingness to participate into the study and comply with its procedures by signing a written informed consent. - Subjects must be >=18 years of age, of either sex and any race. - Women of childbearing potential (includes women who are less than 1 year postmenopausal) must be using an acceptable method of birth control since at least one month prior to visit 1 (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation). Women of childbearing potential should be counseled in the appropriate use of birth control while in this study. - Subjects must be in general good health as confirmed by medical history and, physical examination; i.e., they must be free of any clinically significant disease (other than chronic urticaria [CU]) that would interfere with study evaluations. - Subjects must understand and be able to adhere to the dosing and visit schedules, and agree to complete the questionnaires and to record accurately and consistently in a daily diary symptom severity scores, medication times, concomitant medications, and adverse events. - Subjects must have a history of CU defined as at least 6 weeks of pruritus and hives with hives lasting less than 24 hours and occurring at least 2 days per week. - Subjects must be experiencing a current CU flare with hives present at least 2 days in the week prior to the consent visit/visit 1. - Subjects must have a pruritus score >=2 and a hive score >=1 at consent visit/Visit 1 or during the 12 hours before the consent visit/Visit 1 - Subjects must score the Overall Condition of CU >=2 at both consent visit/Visit 1 and Visit 2 (Baseline). - Subjects must have a total pruritus score of >=11 for the sum of morning (AM) and evening (PM) (reflective) diary scores for the 3 days prior to Visit 2 (Baseline) plus the morning score on the day of Visit 2 - Women of childbearing potential must have a negative urine pregnancy test at Visit 2 (Baseline). Exclusion Criteria: - Women who are pregnant or nursing. - Subjects who have not observed the designated washout periods for any of the prohibited medications - Subjects with asthma - Subjects with drug or food allergies that manifest as skin reactions during 1 year prior to consent visit / visit 1 - Subjects with atopic dermatitis - Subjects with urticaria that is primarily due to physical urticaria or other known etiology (on the basis of clinical history and physical examination). - Subjects with CU unresponsive to antihistamines. - Subjects under regular treatment with NSAIDs. - Subjects who have been hospitalized because of worsening in their CU within 3 months prior to Visit 1 (Screening). - Subjects with a history of hypersensitivity to Desloratadine or any of its excipients. - Subjects previously enrolled into this study (i.e. who have been assigned to treatment). - Subjects who are staff personnel directly involved with the administration of this study. - Subjects who have any clinically significant metabolic, cardiovascular, immunologic, neurologic, hematologic, neoplastic, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the Investigator, may interfere with the study evaluations or affect subject safety. - Subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study. - Subjects with a history of noncompliance with medications or treatment protocols. - Subject treated with any investigational drug in the last 30 days prior to baseline

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
desloratadine
desloratadine 5 mg tablets; one tablet orally once a day for 28 days

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Organon and Co

References & Publications (1)

Seidenari S, Cirillo A, Amoroso S, Flori ML, Amerio P, Ricciuti E, Vena GA, Berardesca E, Le Grazie C and the Italian Study Group on Desloratadine (DL) in Chronic Urticaria. Desloratadine 5 milligrams once daily improves quality of life in chronic idiopat

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline to day 28 in Dermatology Life Quality Index (DLQI) score Baseline and treatment day 28
Secondary Change from Baseline in the DLQI score on treatment days 7, 14, 21 Baseline and treatment days 7, 14, 21
Secondary Change from Baseline in pruritus, the number of hives, sleep quality, and daily activity impairment on treatment days 7, 14, 21, and 28 Baseline and treatment days 7, 14, 21, and 28
Secondary Change from Baseline in the Overall Condition of chronic urticaria on treatment days 14 and 28 Baseline and treatment days 14 and 28
Secondary Percent of subjects who rate their response to therapy as either Complete, Marked, or Moderate Relief on treatment days 14 and 28 Treatment days 14 and 28
Secondary Evaluation of tolerability and safety by clinical laboratory tests Baseline and treatment day 28
Secondary Evaluation of tolerability and safety by adverse events Screening, Baseline, and treatment days 14 and 28
See also
  Status Clinical Trial Phase
Terminated NCT03693625 - A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study Phase 2
Recruiting NCT03545464 - COrticosteroids in acUte uRticAria in emerGency dEpartment Phase 3
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Not yet recruiting NCT00163839 - The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema N/A
Terminated NCT00069329 - Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease N/A
Completed NCT00876369 - Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
Terminated NCT00199238 - Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria Phase 2
Completed NCT02576041 - Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Phase 4
Completed NCT02238249 - Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria N/A
Completed NCT00724698 - Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Completed NCT00001150 - Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers N/A
Completed NCT03296358 - Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department. N/A
Completed NCT00130234 - Effect of Anti-IgE in Chronic Urticaria Phase 2
Completed NCT00368823 - A Trial of Point of Care Information in Ambulatory Pediatrics Phase 3
Completed NCT02424799 - Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 Phase 1
Completed NCT01371877 - The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment N/A
Completed NCT00751218 - A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) Phase 4
Completed NCT03137069 - A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU). Phase 2
Recruiting NCT05115136 - Using Doxepin for Urticaria Phase 3
Terminated NCT02382562 - Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients N/A